Emergent BioSolutions (EBS) Total Non-Current Liabilities (2010 - 2026)

Emergent BioSolutions' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $755.6 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 9.83% year-over-year to $755.6 million in Q1 2026; TTM through Mar 2026 was $755.6 million, a 9.83% decrease from a year earlier, with the FY2025 full-year figure at $742.1 million, down 14.48% from the prior year.
• Total Non-Current Liabilities climbed to $755.6 million in Q1 2026 per EBS's latest filing, from $742.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.7 billion in Q4 2022 and bottomed at $742.1 million in Q4 2025.
• The 5-year median for Total Non-Current Liabilities is $1.1 billion (2024), against an average of $1.1 billion.
• Across the five-year window, Total Non-Current Liabilities jumped 49.08% in 2023 and slumped 35.48% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $1.7 billion in 2022, then sank by 34.09% to $1.1 billion in 2023, then declined by 24.21% to $867.8 million in 2024, then retreated by 14.48% to $742.1 million in 2025, then grew by 1.82% to $755.6 million in 2026.
• Per Business Quant, the three latest EBS Total Non-Current Liabilities figures stand at $755.6 million (Q1 2026), $742.1 million (Q4 2025), and $835.9 million (Q3 2025).